Key Highlights
- Seaport shares are trading down 0.45% at $19.51, against a previous close of $19.60.
- Cash of $403.8 million is expected to fund operations into 2029.
- BUOY-1 Phase 2b depression topline data are expected in the first half of 2027.
Seaport Therapeutics (NASDAQ:SPTX) shares are trading down 0.45% at $19.51, against a previous close of $19.60, after the company reported third-quarter 2026 results and an update on its clinical programs. The net loss was $26.4 million, or $0.49 per share, narrower than the $0.58 loss consensus.
Seaport, based in Boston and founded in 2024, is a clinical-stage biopharmaceutical company developing oral treatments for depression, anxiety and other neuropsychiatric disorders. Its Glyph platform is designed to bypass first-pass liver metabolism, which may improve bioavailability and reduce liver-related side effects. The company priced an upsized IPO in April 2026 that raised about $254.9 million gross, and the stock trades within a 52-week range of $14.85 to $28.38.
GlyphAllo Advances Toward a Depression Readout
GlyphAllo, an oral allopregnanolone prodrug, is in the Phase 2b BUOY-1 trial for major depressive disorder with or without anxious distress. The trial is potentially registration-enabling, enrollment is on track, and topline data are expected in the first half of 2027.
In September, Seaport reported positive topline results from a Phase 1 driving simulation trial in healthy volunteers. Evening dosing of 375 mg did not impair next-morning driving performance versus placebo on Day 5, and a single 250 mg dose met the key secondary endpoint on Day 2. GlyphAllo was well tolerated with no serious adverse events, and the company plans to submit the results to the FDA.
GlyphAgo and the Wider Pipeline
GlyphAgo, an oral agomelatine prodrug, dosed its first patient in a Phase 2a proof-of-pharmacology trial in generalized anxiety disorder with sleep disturbance. The trial tests two dose levels against sleep and anxiety measures, with topline data expected in early 2028. A potentially registration-enabling Phase 2/3 trial in generalized anxiety disorder is planned for the first half of 2027, with data by year-end 2028.
Pharmacokinetic data presented in October showed dose-dependent exposure, no food effect and no accumulation over seven days. Earlier results showed a 6.8-fold increase in agomelatine bioavailability and 10-fold lower variability than unmodified agomelatine. The preclinical Glyph2BLSD program, a non-hallucinogenic neuroplastogen, is expected to complete first-in-human-enabling studies by the end of 2027.
Funding and What to Watch
Cash, cash equivalents and investments totaled $403.8 million at Sept. 30, which the company expects to fund operations into 2029 and through three mid-to-late-stage data readouts. Seaport has no approved products and no revenue.
Seaport's chief executive said the company is well capitalized, with runway through all three upcoming mid-to-late-stage readouts, and noted that a billion people live with mental illness and are waiting for better medicines. Analyst consensus puts the average price target near $37.25, well above the current share price. Shares are essentially unchanged on above-average volume, in a healthcare sector that is steady after a strong prior week for biotech.
The BUOY-1 readout in the first half of 2027 is the nearest catalyst and the most important test of the Glyph approach in depression. The flat share price after the update suggests investors see the quarter as an execution report rather than a new catalyst, with attention now on enrollment progress and the start of the GlyphAgo Phase 2/3 trial.






Please wait processing your request...